{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=91", "query": { "condition": "Lymphoid", "page": 91 }, "page_size": 10 }, "pagination": { "page": 91, "page_size": 10, "total_count": 3083, "total_pages": 309, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=92&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=90&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T10:10:05.785Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00295932", "title": "Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2005-12-13", "completion_date": "2018-03-11", "has_results": true, "last_update_posted_date": "2018-11-20", "last_synced_at": "2026-11-14T10:10:05.785Z", "location_count": 8, "location_summary": "Atlanta, Georgia • Basking Ridge, New Jersey • New Brunswick, New Jersey + 4 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00295932" }, { "nct_id": "NCT00089076", "title": "MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Grade III Lymphomatoid Granulomatosis", "B-cell Chronic Lymphocytic Leukemia", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Refractory Hairy Cell Leukemia", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Testicular Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "ipilimumab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2004-06", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2014-05-30", "last_synced_at": "2026-11-14T10:10:05.785Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089076" }, { "nct_id": "NCT03654404", "title": "A Proof-of-Concept Trial of a Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hematologic Malignancy", "Hematopoietic/Lymphoid Cancer", "Blood Cancer" ], "interventions": [ { "name": "Positive Psychology Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 29, "start_date": "2018-09-11", "completion_date": "2021-07-31", "has_results": true, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-11-14T10:10:05.785Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03654404" }, { "nct_id": "NCT00004258", "title": "EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Precancerous/Nonmalignant Condition", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "cilengitide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "1999-12", "completion_date": "2001-09", "has_results": false, "last_update_posted_date": "2014-09-17", "last_synced_at": "2026-11-14T10:10:05.785Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004258" }, { "nct_id": "NCT05775406", "title": "Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myeloid Malignancies", "Acute Lymphocytic Leukemia", "Lymphomas", "Advanced Solid Tumors" ], "interventions": [ { "name": "KT-253", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kymera Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2023-05-15", "completion_date": "2024-12-18", "has_results": false, "last_update_posted_date": "2025-01-27", "last_synced_at": "2026-11-14T10:10:05.785Z", "location_count": 11, "location_summary": "Scottsdale, Arizona • Sacramento, California • Boston, Massachusetts + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05775406" }, { "nct_id": "NCT04189952", "title": "Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B Cell Lymphoma", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Leukemia", "Marginal Zone Lymphoma" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2020-09-22", "completion_date": "2022-03-01", "has_results": true, "last_update_posted_date": "2025-05-31", "last_synced_at": "2026-11-14T10:10:05.785Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04189952" }, { "nct_id": "NCT00118326", "title": "Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Kidney Cancer", "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Neuroblastoma", "Sarcoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": null, "start_date": "2003-08", "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2010-05-14", "last_synced_at": "2026-11-14T10:10:05.785Z", "location_count": 2, "location_summary": "Nashville, Tennessee • Seattle, Washington", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00118326" }, { "nct_id": "NCT00759798", "title": "Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Leukemia" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 289, "start_date": "2008-08-13", "completion_date": "2020-07-22", "has_results": true, "last_update_posted_date": "2021-09-05", "last_synced_at": "2026-11-14T10:10:05.785Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00759798" }, { "nct_id": "NCT02259348", "title": "Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia (ALL)", "Acute Myeloid Leukemia (AML)", "Myeloid Sarcoma", "Chronic Myelogenous Leukemia (CML)", "Juvenile Myelomonocytic Leukemia (JMML)", "Myelodysplastic Syndrome (MDS)", "Non-Hodgkin Lymphoma (NHL)" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "G-CSF", "type": "BIOLOGICAL" }, { "name": "Interleukin-2", "type": "BIOLOGICAL" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Natural killer cell therapy", "type": "BIOLOGICAL" }, { "name": "T-cell depleted HPC transplant", "type": "BIOLOGICAL" }, { "name": "CD45RA-depleted HPC transplant", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 12, "start_date": "2014-10", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-11-14T10:10:05.785Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02259348" }, { "nct_id": "NCT01039376", "title": "Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukaemia, Lymphocytic, Chronic" ], "interventions": [ { "name": "Ofatumumab", "type": "BIOLOGICAL" }, { "name": "Observation", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 480, "start_date": "2010-05-06", "completion_date": "2018-06-26", "has_results": true, "last_update_posted_date": "2019-07-30", "last_synced_at": "2026-11-14T10:10:05.785Z", "location_count": 43, "location_summary": "Gilbert, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 37 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01039376" } ] }